Lysophosphatidylcholine (LPC) is increasingly recognized as a key marker/factor positively
associated with cardiovascular and neurodegenerative diseases. However, findings from …

Lysophosphatidylcholine (LPC) is the main component of oxidatively damaged low-density
lipoprotein (oxLDL). LPC originates from the cleavage of phosphatidylcholine by …

1.1. Discovery of the Phospholipase A2 Superfamily Phospholipases represent one of the
earliest enzyme activities to be identified and studied, and the phospholipase A2 (PLA2) …

Background Lipoprotein-associated phospholipase A (2)(Lp-PLA (2)), an inflammatory
enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials …

Inflammation has been long regarded as a key contributor to atherosclerosis. Inflammatory
cells and soluble mediators play critical roles throughout arterial plaque development and …

Phospho-and sphingolipids are crucial cellular and intracellular compounds. These lipids
are required for active transport, a number of enzymatic processes, membrane formation …

Objectives—To determine whether the level of lysophosphatidylcholine (lysoPC) generated
by lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with severity of …

Background Proinflammatory (M1) macrophages and anti-inflammatory (M2) macrophages
have been identified in atherosclerotic plaques. While these macrophages have been …

Today there exists only one FDA-approved treatment for ischemic stroke; ie, the serine
protease tissue-type plasminogen activator (tPA). In the aftermath of the failed stroke clinical …

Lipoprotein-associated phospholipase A 2 (Lp-PLA 2), also known as platelet-activating
factor acetylhydrolase (PAF-AH), is a unique member of the phospholipase A 2 superfamily …